Effect of opioid dependence pharmacotherapies on zidovudine disposition.

Injection drug users are frequently infected with human immunodeficiency virus (HIV) and receive opioid dependence pharmacotherapies and zidovudine (ZDV), the latter as a component of highly active antiretroviral therapy. We previously reported that methadone substantially increases ZDV concentrations. We now report on oral ZDV pharmacokinetics in 52 subjects receiving the opioid dependence pharmacotherapies l-alpha-acetylmethadol LAAM, buprenorphine, or naltrexone, and 17 non-opioid-treated controls. Relative to the area under the time-concentration curve (AUC) of ZDV in control subjects, no statistically significant differences in ZDV AUC were observed in participants treated with LAAM (p = .75), buprenorphine (p = .37), or naltrexone (p = .34). While methadone maintenance may result in ZDV toxicity and possibly require dose adjustments, other opioid pharmacotherapies should not produce ZDV toxicity.

[1]  D. Back,et al.  The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. , 2001, British journal of clinical pharmacology.

[2]  P. Jatlow,et al.  Interaction of methadone with didanosine and stavudine. , 2000, Journal of acquired immune deficiency syndromes.

[3]  G. Badger,et al.  Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. , 2000, The American journal on addictions.

[4]  E. McCance-Katz,et al.  Decrease in methodone levels with nelfinavir mesylate. , 2000, The American journal of psychiatry.

[5]  F. Altice,et al.  Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. , 1999, AIDS.

[6]  K. Lohr,et al.  Pharmacological treatment of alcohol dependence: a review of the evidence. , 1999, JAMA.

[7]  P. Jatlow,et al.  Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[8]  V. M. Shadle,et al.  Self-reported antiretroviral therapy in injection drug users. , 1998, JAMA.

[9]  B. Yip,et al.  Barriers to use of free antiretroviral therapy in injection drug users. , 1998, JAMA.

[10]  B. Rounsaville,et al.  A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. , 1998, The American journal of medicine.

[11]  D. Ziedonis,et al.  Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. , 1997, Archives of general psychiatry.

[12]  T. S. Jones,et al.  Prevention of HIV/AIDS and other blood-borne diseases among injection drug users. A national survey on the regulation of syringes and needles. , 1997, JAMA.

[13]  S. O'Malley,et al.  Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. , 1996, Alcohol and alcoholism (Oxford, Oxfordshire). Supplement.

[14]  M. Stitzer,et al.  Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. , 1996, Journal of clinical psychopharmacology.

[15]  T. Reisine.  Opioid analgesics and antagonists , 1996 .

[16]  B. Rounsaville,et al.  A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. , 1996, The American journal of drug and alcohol abuse.

[17]  P. Selwyn,et al.  Medical care for injection-drug users with human immunodeficiency virus infection. , 1994, The New England journal of medicine.

[18]  P. Selwyn,et al.  Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. , 1992, The New England journal of medicine.

[19]  P. Selwyn,et al.  Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. , 1992, Journal of acquired immune deficiency syndromes.

[20]  Mulé Sj,et al.  Naltrexone (Trexan): a review of hepatotoxicity issues. , 1986 .

[21]  C. Klett,et al.  A cooperative clinical study of methadyl acetate. I. Three-times-a-week regimen. , 1978, Archives of general psychiatry.